Page 377 - PROGRAMME2018

COMPANY SYMPOSIA – FORUM (AUDITORIUM)
Monday, 2 July 2018:
11:45 - 13:00 Company Symposium Merck
“How to improve ART efficiency and risk management to shorten time to live birth”
Chair: Ernesto Bosch, Valenica Spain
11:45 - 11:50 11:50 - 11:55 11:55 - 12:15 12:15 - 12:35 12:35 - 12:55 12:55 - 13:00
Chair: Tony Gordon, CooperGenomics
• Where Are We Now: The Challenges and Benefits of Genetics in IVF Tony Gordon (VP Business Development, CooperGenomics)
• Next Steps in Preimplantation Genetic Testing Santiago Munné (Co-Founder, CooperGenomics)
• CRISPR-Cas9 in Assisted Reproduction: The Science and the Ethical Challenges Mark Hughes (Co-Founder and Chief Medical Officer, CooperGenomics)
17:00 - 18:15 Company Symposium Gedeon Richter
“The future of cryopreservation in ART”
Chairs: Professor Dr Ariane Germeyer MD, PhD – Germany Professor Dr Nikolaos Polyzos MD, PhD – Spain
• Freeze-all in ART: a shift in practice or still a walk on thin ice? Professor Dr Michel De Vos MD, PhD – Belgium
• Can we optimise the reproductive outcomes of fresh and frozen embryo transfer? Professor Dr Peter Humaidan MD, DMSc – Denmark
• How to optimise the ‘freeze-all’ procedure: for whom, when and how? Dr Ernesto Bosch MD, PhD – Spain
Welcome
Thomas D’Hooghe (Darmstadt, Germany)
Delphi consensus paper on how specific treatment approaches can shorten TTLB
Ernesto Bosch (Valencia, Spain)
Optimize oocytes yield to maximize live births
Sandro Esteves (Sao Paulo, Brazil)
Remove risks in ART without compromising other outcomes such as live birth rate
Zi-Jiang Chen (Shandong, China)
Embrace Fertility Technologies to expand ART knowledge and patient’s opportunities
Marcos Meseguer (Valencia, Spain)
Summary and Closing remarks
Ernesto Bosch (Valencia, Spain)
Company Symposium Cooper Surgical
Advancing Technologies For Reproductive Genetics: Where Are We Heading?
14:00 - 15:15
FINAL PROGRAMME I BARCELONA, SPAIN – 1 TO 4 JULY 2018
377
COMPANY SYMPOSIA